Patents by Inventor Dean Felsher

Dean Felsher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Enhancing Immunogenicity of Cancers
    Publication number: 20220283165
    Abstract: Provided are methods of enhancing immunogenicity of cancers. In certain aspects, the methods include administering an effective amount of a sialic acid modulator to an individual identified as having a cancer comprising dysregulated Myc. According to some aspects, the methods include administering an effective amount of a disialyl-T modulator to an individual identified as having a cancer comprising cell surface expression of disialyl-T. In certain aspects, the methods include administering an effective amount of an agent to an individual identified as having a cancer comprising cell surface expression of a glycoprotein comprising an O-glycosylated mucin-like domain, where the agent modulates the glycoprotein. Also provided are methods of assessing whether a cancer of an individual comprises dysregulated Myc.
    Type: Application
    Filed: July 10, 2020
    Publication date: September 8, 2022
    Inventors: Dean Felsher, Carolyn R. Bertozzi, Anja Deutzmann, Benjamin Smith, Simon Wisnovsky
  • Method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis
    Patent number: 10894988
    Abstract: Through genomic analysis a 12-gene signature comprising up-regulated genes and down-regulated genes has been identified that is highly predictive of metastasis and overall survival in human patients with HCC. Another aspect of the disclosure methods of determining the metastatic status of an hepatocellular carcinoma of a patient, comprising obtaining a first differential gene expression profile from a carcinoma sample from a subject having an hepatocellular carcinoma and creating a report summarizing the normalized data obtained by the first gene expression analysis and including a determination of the metastatic status of the hepatic carcinoma.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: January 19, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Dean Felsher, Meital Ryan, Robert Tibshirani
  • METHOD OF DETERMINING THE PROGNOSIS OF HEPATOCELLULAR CARCINOMAS USING A MULTIGENE SIGNATURE ASSOCIATED WITH METASTASIS
    Publication number: 20190040469
    Abstract: Through genomic analysis a 12-gene signature comprising up-regulated genes and down-regulated genes has been identified that is highly predictive of metastasis and overall survival in human patients with HCC. Another aspect of the disclosure methods of determining the metastatic status of an hepatocellular carcinoma of a patient, comprising obtaining a first differential gene expression profile from a carcinoma sample from a subject having an hepatocellular carcinoma and creating a report summarizing the normalized data obtained by the first gene expression analysis and including a determination of the metastatic status of the hepatic carcinoma.
    Type: Application
    Filed: September 9, 2016
    Publication date: February 7, 2019
    Inventors: Dean Felsher, Meital Ryan, Robert Tibshirani